ArticlePloS one2026
Multi-task gradient boosting with multi-modal molecular representations for simultaneous prediction of drug clearance and volume of distribution.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prediction of pharmacokinetic parameters-particularly drug clearance (CL) and volume of distribution (VD)-is critical in early drug development, yet existing approaches largely treat these physiologically correlated endpoints as independent tasks and rely on single molecular data modalities. To address these gaps, we propose a Multi-Task Gradient Boosting Machine (MTGBM) framework that simultaneously predicts CL and VD by integrating three complementary molecular modalities-CNN-based structural embeddings, MLP-derived descriptor embeddings, and physicochemical and preclinical PK parameters-into shared decision trees. MTGBM outperformed single-task LightGBM baselines in MSE and R² for both targets, with CL GMFE also showing improvement, except for VD GMFE in the low VD range. These findings were further reinforced by 10 repeated random splits of the entire dataset. SHAP analysis revealed complementary contributions from all three modalities and suggested cross-target information sharing between CL and VD embeddings. These results establish MTGBM as a proof-of-concept for multi-modal, multi-task pharmacokinetic modeling, offering a foundation for future integration with larger datasets or foundation model-derived representations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.